U-77891 manufacturers
- U-77891
-
- $0.00 / 1kg
-
2024-04-12
- CAS:119878-31-8
- Min. Order: 1kg
- Purity: 0.99
- Supply Ability: 10T
|
| | U-77891 Basic information |
| Product Name: | U-77891 | | Synonyms: | Benzamide, 3,4-dibromo-N-methyl-N-[(5R,6S)-1-methyl-1-azaspiro[4.5]dec-6-yl]-, rel-;trans-3,4-Dibromo-N-methyl-N-(1-methyl-1-azaspiro[4.5]dec-6-yl)-benzamide;U-77891 | | CAS: | 119878-31-8 | | MF: | C18H24Br2N2O | | MW: | 444.2 | | EINECS: | | | Product Categories: | | | Mol File: | 119878-31-8.mol |  |
| | U-77891 Chemical Properties |
| Boiling point | 522.7±50.0 °C(Predicted) | | density | 1.55±0.1 g/cm3(Predicted) | | pka | 9.72±0.40(Predicted) |
| | U-77891 Usage And Synthesis |
| Description | U-77891 is an opioid analgesic drug that was first synthesized in 1983 by the Upjohn company.[1] It was originally synthesized to prove that the removal of a single methylene spacer of the benzamide would alter a κ-opioid receptor agonist such as U-50488 into an μ-opioid receptor agonist, as well as producing a semi-rigid derivative of U-47700. This would help elucidate the relative positions of the hydrogen-bond acceptors and substituted aromatic system to find the compound with the lowest Ki value in a series of benzamide opioids dating back to the 1970s.[2] The original work found a mixture of agonists and antagonists.
wikipedia | | Uses | trans-3,4-Dibromo-N-methyl-N-(1-methyl-1-azaspiro[4.5]dec-6-yl)-benzamide is a μ-opioid, δ-opioid and κ-opioid receptors agonist and an analgesic agent. |
| | U-77891 Preparation Products And Raw materials |
|